Patents Assigned to Boston Biomedical, Inc.
-
Publication number: 20200392098Abstract: The present invention provides compounds represented by formula (1A), or pharmaceutically acceptable salts. Compounds represented by formula (1A), or pharmaceutically acceptable salts thereof, wherein A1 and A2 are identical or different, and each independently —C(?O)B, —C(?O)CR3AR3BB, —CO2B, —C(?S)OB, —CONR3CB, —C(?S)NR3CB, a hydrogen atom, or the like, wherein A1 and A2 are not both hydrogen atoms, wherein B is an optionally substituted 3- to 12-membered monocyclic or polycyclic heterocyclic group, an optionally substituted 3- to 12-membered cyclic amino group, or a group represented by the following formula (B), wherein the 3- to 12-membered monocyclic or polycyclic heterocyclic group and the 3- to 12-membered cyclic amino group have at least one or more secondary nitrogen atoms in the ring; R1 is a hydrogen atom or the like; R2A, R2B, R2C, and R2D are identical or different, and each independently a hydrogen atom or the like; and R8 is alkyl. wherein * denotes a bonding position.Type: ApplicationFiled: August 28, 2020Publication date: December 17, 2020Applicants: BOSTON BIOMEDICAL, INC., SUMITOMO DAINIPPON PHARMA CO., LTD.Inventors: Hitoshi BAN, Seiji KAMIOKA, Yusuke SAWAYAMA, Chiang Jia LI
-
Patent number: 10800752Abstract: The present invention provides compounds represented by formula (1A), or pharmaceutically acceptable salts. Compounds represented by formula (1A), or pharmaceutically acceptable salts thereof, wherein A1 and A2 are identical or different, and each independently —C(?O)B, —C(?O)CR3AR3BB, —CO2B, —C(?S)OB, —CONR3CB, —C(?S)NR3CB, a hydrogen atom, or the like, wherein A1 and A2 are not both hydrogen atoms, wherein B is an optionally substituted 3- to 12-membered monocyclic or polycyclic heterocyclic group, an optionally substituted 3- to 12-membered cyclic amino group, or a group represented by the following formula (B), wherein the 3- to 12-membered monocyclic or polycyclic heterocyclic group and the 3- to 12-membered cyclic amino group have at least one or more secondary nitrogen atoms in the ring; R1 is a hydrogen atom or the like; R2A, R2B, R2C, and R2D are identical or different, and each independently a hydrogen atom or the like; and R8 is alkyl. wherein * denotes a bonding position.Type: GrantFiled: November 19, 2018Date of Patent: October 13, 2020Assignees: BOSTON BIOMEDICAL, INC., SUMITOMO DAINIPPON PHARMA CO., LTD.Inventors: Hitoshi Ban, Seiji Kamioka, Yusuke Sawayama, Chiang Jia Li
-
Patent number: 10683274Abstract: The present invention provides a compound of the following Formula (1) or a pharmaceutically acceptable salt thereof: wherein X is an oxygen atom and the like; Y is —CO—, —SO2— and the like; R1 is an optionally-substituted C1-6 alkyl group, an optionally-substituted C1-6 alkylcarbonyl group and the like; R2 is an optionally-substituted C1-6 alkyl group, an optionally-substituted C1-6 alkoxy group, an optionally-substituted amino group, an optionally-substituted 5- to 12-membered monocyclic or polycyclic saturated heterocyclic group and the like; R3, R4, R5, and R6 are independently a hydrogen atom and the like which exhibits excellent effects in suppressing the proliferation and sphere-forming ability of cancer cells, and can be useful as an antitumor drug or cell growth inhibitor.Type: GrantFiled: November 29, 2018Date of Patent: June 16, 2020Assignee: Boston Biomedical, Inc.Inventors: Toshihiko Sone, Wataru Hirose, Naoaki Shimada, Chiang Li, Wei Li, David Leggett
-
Patent number: 10646464Abstract: Methods for treating advanced thymoma and thymic carcinoma in a subject comprising administering and kits comprising at least one paclitaxel compound and at least one compound of formula (I) (2-acetylnaphtho[2,3-b]furan-4,9-dione) as disclosed herein.Type: GrantFiled: May 16, 2018Date of Patent: May 12, 2020Assignee: Boston Biomedical, Inc.Inventors: Chiang Jia Li, Youzhi Li, Wei Li, Matthew Hitron, Yuan Gao
-
Patent number: 10543189Abstract: The invention provides naphthofuran compounds, polymorphs of naphthofuran compounds, naphthofuran compounds in particle form, purified compositions that contain one or more naphthofuran compounds, purified compositions that contain one or more naphthofuran compounds in particle form, and methods of using these naphthofuran compounds, polymorphs, purified compositions and/or particle forms to treat subjects in need thereof.Type: GrantFiled: August 16, 2019Date of Patent: January 28, 2020Assignee: Boston Biomedical, Inc.Inventors: Chiang Jia Li, Wei Li, David Leggett, Youzhi Li, David Kerstein, Matthew Hitron
-
Patent number: 10377731Abstract: The present invention relates to the composition and methods of use of Stat3 pathway inhibitors or cancer stem cell inhibitors in combination treatment of cancer.Type: GrantFiled: January 14, 2019Date of Patent: August 13, 2019Assignee: Boston Biomedical, Inc.Inventors: Chiang Jia Li, Keith Mikule, Youzhi Li
-
Publication number: 20190084955Abstract: The present invention provides compounds represented by formula (1A), or pharmaceutically acceptable salts. Compounds represented by formula (1A), or pharmaceutically acceptable salts thereof, wherein A1 and A2 are identical or different, and each independently —C(?O)B, —C(?O)CR3AR3BB, —CO2B, —C(?S)OB, —CONR3CB, —C(?S)NR3CB, a hydrogen atom, or the like, wherein A1 and A2 are not both hydrogen atoms, wherein B is an optionally substituted 3- to 12-membered monocyclic or polycyclic heterocyclic group, an optionally substituted 3- to 12-membered cyclic amino group, or a group represented by the following formula (B), wherein the 3- to 12-membered monocyclic or polycyclic heterocyclic group and the 3- to 12-membered cyclic amino group have at least one or more secondary nitrogen atoms in the ring; R1 is a hydrogen atom or the like; R2A, R2B, R2C, and R2D are identical or different, and each independently a hydrogen atom or the like; and R8 is alkyl. wherein * denotes a bonding position.Type: ApplicationFiled: November 19, 2018Publication date: March 21, 2019Applicants: BOSTON BIOMEDICAL, INC., SUMITOMO DAINIPPON PHARMA CO., LTD.Inventors: Hitoshi BAN, Seiji KAMIOKA, Yusuke SAWAYAMA, Chiang Jia LI
-
Patent number: 10183925Abstract: The present invention provides compounds represented by formula (1A), or pharmaceutically acceptable salts. Compounds represented by formula (1A), or pharmaceutically acceptable salts thereof, wherein A1 and A2 are identical or different, and each independently —C(?O) B, —C(?O)CR3AR3BB, —CO2B, —C(?S)OB, —CONR3CB, —C(?S)NR3CB, a hydrogen atom, or the like, wherein A1 and A2 are not both hydrogen atoms, wherein B is an optionally substituted 3- to 12-membered monocyclic or polycyclic heterocyclic group, an optionally substituted 3- to 12-membered cyclic amino group, or a group represented by the following formula (B), wherein the 3- to 12-membered monocyclic or polycyclic heterocyclic group and the 3- to 12-membered cyclic amino group have at least one or more secondary nitrogen atoms in the ring; R1 is a hydrogen atom or the like; R2A, R2B, R2C, and R2D are identical or different, and each independently a hydrogen atom or the like; and R8 is alkyl. wherein * denotes a bonding position.Type: GrantFiled: March 25, 2016Date of Patent: January 22, 2019Assignees: BOSTON BIOMEDICAL, INC., SUMITOMO DAINIPPON PHARMA CO., LTD.Inventors: Hitoshi Ban, Seiji Kamioka, Yusuke Sawayama, Chiang Jia Li
-
Publication number: 20180250261Abstract: Methods comprising administering and kits comprising at least one compound of formula A: (A) prodrugs, derivatives, pharmaceutically acceptable salts of any of the foregoing, and solvates of any of the foregoing, and at least one compound of formula B: (B) prodrugs, derivatives, pharmaceutically acceptable salts of any of the foregoing, and solvates of any of the foregoing.Type: ApplicationFiled: April 26, 2016Publication date: September 6, 2018Applicant: BOSTON BIOMEDICAL, INC.Inventors: Chiang J. LI, Youzhi LI, Harry ROGOFF, Yuan GAO, Janet HUANG
-
Publication number: 20180250260Abstract: Methods comprising administration of, and kits comprising, at least one compound of formula (I) FOLFIRI, and optionally at least one angiogenesis inhibitor.Type: ApplicationFiled: April 18, 2016Publication date: September 6, 2018Applicant: BOSTON BIOMEDICAL., INC.Inventors: Chiang J LI, Wei LI, Youzhi LI, Laura BORODYANSKY, Yuan GAO, David P. KERSTEIN
-
Publication number: 20180193318Abstract: The invention provides thiazole-substituted indolin-2-ones as inhibitors of cancer stem cell pathway kinases (CSCPK) and related kinases, and methods of using these compounds, to treat subjects in need thereof.Type: ApplicationFiled: September 15, 2017Publication date: July 12, 2018Applicant: Boston Biomedical, Inc.Inventors: Chiang Jia Li, Youzhi Li
-
Patent number: 10017488Abstract: The present invention provides a compound of the following Formula (1) or a pharmaceutically acceptable salt thereof: wherein X is an oxygen atom and the like; Y is —CO—, —SO2— and the like; R1 is an optionally-substituted C1-6 alkyl group, an optionally-substituted C1-6 alkylcarbonyl group and the like; R2 is an optionally-substituted C1-6 alkyl group, an optionally-substituted C1-6 alkoxy group, an optionally-substituted amino group, an optionally-substituted 5- to 12-membered monocyclic or polycyclic saturated heterocyclic group and the like; R3, R4, R5, and R6 are independently a hydrogen atom and the like which exhibits excellent effects in suppressing the proliferation and sphere-forming ability of cancer cells, and can be useful as an antitumor drug or cell growth inhibitor.Type: GrantFiled: February 6, 2015Date of Patent: July 10, 2018Assignee: Boston Biomedical, Inc.Inventors: Toshihiko Sone, Wataru Hirose, Naoaki Shimada, Chiang J. Li, Wei Li, David Leggett
-
Publication number: 20180111914Abstract: The present invention provides compounds represented by formula (1A), or pharmaceutically acceptable salts. Compounds represented by formula (1A), or pharmaceutically acceptable salts thereof, wherein A1 and A2 are identical or different, and each independently —C(?O) B, —C(?O)CR3AR3BB, —CO2B, —C(?S)OB, —CONR3CB, —C(?S)NR3CB, a hydrogen atom, or the like, wherein A1 and A2 are not both hydrogen atoms, wherein B is an optionally substituted 3- to 12-membered monocyclic or polycyclic heterocyclic group, an optionally substituted 3- to 12-membered cyclic amino group, or a group represented by the following formula (B), wherein the 3- to 12-membered monocyclic or polycyclic heterocyclic group and the 3- to 12-membered cyclic amino group have at least one or more secondary nitrogen atoms in the ring; R1 is a hydrogen atom or the like; R2A, R2B, R2C, and R2D are identical or different, and each independently a hydrogen atom or the like; and R8 is alkyl. wherein * denotes a bonding position.Type: ApplicationFiled: March 25, 2016Publication date: April 26, 2018Applicants: BOSTON BIOMEDICAL, INC., SUMITOMO DAINIPPON PHARMA CO., LTD.Inventors: Hitoshi BAN, Seiji KAMIOKA, Yusuke SAWAYAMA, Chiang Jia LI
-
Publication number: 20180098959Abstract: Methods comprising administration of and kits comprising at least one compound of formula (I); and at least one additional anti-cancer therapy chosen from panitumumab, cetuximab, capecitabine, CAPDX, regorafenib, and FOLFOX.Type: ApplicationFiled: April 18, 2016Publication date: April 12, 2018Applicant: BOSTON BIOMEDICAL, INC.Inventors: Chiang J. LI, Youzhi LI, Laura BORODYANSKY, Yuan GAO, David LEGGETT, David P. KERSTEIN
-
Publication number: 20180085341Abstract: Methods comprising administering and kits comprising at least one paclitaxel compound and at least one compound of formula (I).Type: ApplicationFiled: April 18, 2016Publication date: March 29, 2018Applicant: BOSTON BIOMEDICAL, INC.Inventors: Chiang J. LI, Wei LI, Youzhi LI, Matthew J. Hitron, Yuan GAO
-
Publication number: 20180030022Abstract: The present invention relates to the use of a novel class of cancer stem cell pathway (CSCP) inhibitors; to methods of using such compounds to treat refractory, recurrent, or metastatic cancers; to methods of selective killing cancer cells by using such compounds with specific administration regimen; to methods of targeting cancer stem cells by inhibiting Stat3 pathway; to methods of using novel compounds in the treatment of conditions or disorders in a mammal related to aberrant Stat3 pathway activity; and to processes for preparing such compounds and intermediates thereof, and to the pharmaceutical compositions of relevant compounds, and to the specific methods of administration of these compounds.Type: ApplicationFiled: July 20, 2017Publication date: February 1, 2018Applicant: Boston Biomedical, Inc.Inventors: Chiang Jia Li, Harry Rogoff, Youzhi Li, Jifeng Liu, Wei Li
-
Publication number: 20180030021Abstract: The present invention relates to the composition and methods of use of Stat3 pathway inhibitors or cancer stem cell inhibitors in combination treatment of cancer.Type: ApplicationFiled: July 11, 2017Publication date: February 1, 2018Applicant: Boston Biomedical, Inc.Inventors: Chiang Jia Li, Keith Mikule, Youzhi Li
-
Patent number: 9834532Abstract: The present invention relates to a novel naphtho class of compounds as Stat3 pathway inhibitors and as cancer stem cell inhibitors; to methods of using such compounds to treat cancer; to methods of using such compounds to treat disorders in a mammal related to aberrent Stat3 pathway activity; to pharmaceutical compositions containing such compounds.Type: GrantFiled: September 29, 2014Date of Patent: December 5, 2017Assignee: BOSTON BIOMEDICAL, INC.Inventors: Zhiwei Jiang, Chiang Jia Li, Wei Li, David Leggett
-
Publication number: 20170319537Abstract: The invention provides naphthofuran compounds, polymorphs of naphthofuran compounds, naphthofuran compounds in particle form, purified compositions that contain one or more naphthofuran compounds, purified compositions that contain one or more naphthofuran compounds in particle form, methods of producing these naphthofuran compounds, polymorphs, purified compositions and/or particle forms, and methods of using these naphthofuran compounds, polymorphs, purified compositions and/or particle forms to treat subjects in need thereof.Type: ApplicationFiled: July 5, 2017Publication date: November 9, 2017Applicant: BOSTON BIOMEDICAL, INC.Inventors: Chiang Jia Li, David Leggett, Youzhi Li, Wei Li
-
Patent number: 9795595Abstract: The invention provides thiazole-substituted indolin-2-ones as inhibitors of cancer stem cell pathway kinases (CSCPK) and related kinases, and methods of using these compounds, to treat subjects in need thereof.Type: GrantFiled: January 26, 2015Date of Patent: October 24, 2017Assignee: Boston Biomedical, Inc.Inventors: Chiang Jia Li, Youzhi Li